# US 2017/0283491 A1 · Method of providing disease-specific binding molecules and targets

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283491 A1
- Document ID: US20170283491A1
- Status: Published application
- Kind: A1
- Application number: 15/593,845
- Filed: 2017-05-12
- Published: 2017-10-05
- Earliest claimed: 2007-01-05
- Assignees: University of Zurich
- Applicants: University of Zurich
- Inventors: Roger Nitsch; Christoph Hock; Christoph Esslinger; Marlen Knobloch; Kathrin Tissot; Jan Grimm
- Web page: https://patentgrep.com/patent/US20170283491A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 51/1018: {against material from animals or humans}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- G01N 33/6854: {Immunoglobulins}
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/30: characterized by aspects of specificity or valency
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2333/4709: Amyloid plaque core protein
- G01N 2800/2821: Alzheimer
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.

## Claims

### Claim at position 1

1-51. (canceled)

### Claim 52

A method of obtaining a monoclonal antibody specific for a pathological variant of an endogenous protein associated with a disorder characterized by the presence of pathological protein structures of the pathological variant of the endogenous protein comprising:
(a) subjecting a sample which comprises or is derived from memory B cells from (i) a subject who is symptom-free but affected with, or at risk of developing, the disorder, or (ii) a patient with an unusually stable disease course of the disorder, to a specimen displaying said pathological protein structures of the protein variant and wherein binding of an antibody in the sample to said specimen but not to tissues without said pathological structures indicates the presence in the sample of an antibody specific for the disorder-associated pathological variant of the endogenous protein; and
(b) identifying and isolating the antibody which binds to said specimen but not to tissues without said pathological structures as follows:
(i) purifying memory B cells which do not express IgM from the sample in which the antibody which binds to said specimen but not to tissue without said pathological structures is present;
(ii) obtaining immunoglobulin gene repertoire for said antibody from said memory B cells;
(iii) using said gene repertoire to express said antibody;
(iv) rescreening on tissue microarray and/or ELISA upon expression of the antibody; and
(v) isolating the antibody which specifically binds to said specimen but not to tissue without said pathological protein structures,
wherein the variant of the endogenous protein is not derived from beta-amyloid or AIAPP (islet amyloid polypeptide).

### Claim 53 (depends on 52)

The method of claim 52, wherein said specimen comprises tissue derived from a human patient with the disorder or an animal model of the disorder, wherein the cells or tissue comprise said pathological protein structures.

### Claim 54 (depends on 52)

The method of claim 52, wherein the disorder is a neurodegenerative disease, a protein-misfolding disease, tissue amyloidosis or another disease involving pathological protein deposits.

### Claim 55 (depends on 52)

The method of claim 52, wherein said disorder is a neurological disorder.

### Claim 56 (depends on 52)

The method of claim 52, wherein the variant of the endogenous protein is derived from SAA (Serum-Amyloid-Protein A), AL (k or l-light chains of Immunoglobulins), AH (gl Ig-heavy chains), ATTR (Transthyretin, Serum-Prealbumin), AApo-A-1 (Apolipoprotein A1), AApoA2 (Apolipoprotein A2), AGeI (Gelsolin), ACys (Cystatin C), ALys (Lysozyme), AFib (Fibrinogen), tau, α-synuclein, Beta-amyloid2M (beta2-microglobulin), APrP (Prion protein), ACaI (Procalcitonin), APro (Prolactin), Ains (Insulin), AMed (Lactadherin), Aker (Kerato-epithelin), ALac (Lactoferrin), Abri (AbriPP), ADan (ADanPP), AANP (Atrial natriuretical peptide), Superoxide dismutase-1 (SOD1), Huntington (containing polyglutamine repeat expansion), or Ataxin (containing polyglutamine repeat expansion).

### Claim 57 (depends on 52)

The method of claim 52, wherein either said patient or said subject is a human.

### Claim 58 (depends on 52)

The method of claim 52, wherein said subject has been determined to be affected with a not yet manifested disorder or at risk to develop the disorder by the presence or the absence of a surrogate marker selected from the group consisting of old age, ApoE genotype, APP genotype, PS1 genotype, isoprostanes, Tau, and phospho-Tau.

### Claim 59 (depends on 52)

The method of claim 52, wherein the sample is obtained from a patient fulfilling the following criteria:
(i) being 65 years of age or older;
(ii) having full cognitive capacity and good health; and
(iii) having no clinical signs of dementia.

### Claim 60 (depends on 52)

The method of claim 52 wherein step (b) (ii) comprises the steps of:
(ii)(A) obtaining mRNA from said B cells or memory B cells;
(ii) (B) obtaining cDNA from the mRNA of step (ii)(A); and
(ii) (C) using a primer extension reaction to amplify from said cDNA the fragments encoding the heavy chains (HC) and the kappa light chains (LC) of said antibodies.

### Claim 61 (depends on 60)

A method for preparing a recombinant human-derived monoclonal antibody comprising first performing the steps of claim 60, recovering the amplified cDNA fragments encoding the heavy chains (HC) and the kappa light chains (LC), inserting the variable heavy and light chain cDNA fragment into expression vectors that complement the variable region sequence with a sequence encoding an appropriate constant region, and treating the expression vectors so as to prepare the human-derived monoclonal antibody.

### Claim 62 (depends on 61)

A method of preparing a pharmaceutical composition of a recombinant human-derived monoclonal antibody comprising first the steps of the method of claim 61 and formulating the recombinant human-derived monoclonal antibody with a pharmaceutically acceptable carrier in a pharmaceutical composition.

### Claim 63 (depends on 60)

A method for preparing a recombinant human-derived monoclonal antibody for therapeutic applications comprising first performing the steps of claim 60, recovering the amplified cDNA fragments encoding the heavy chains (HC) and the kappa light chains (LC), inserting the variable heavy and light chain cDNA fragment into expression vectors that complement the variable region sequence with a sequence encoding an appropriate constant region, and treating the expression vectors so as to prepare the human-derived monoclonal antibody for therapeutic applications.

### Claim 64 (depends on 63)

The method of claim 63, wherein the therapeutic applications include tumor diseases, inflammatory diseases and diseases of the central nervous system, like Alzheimer's disease, Parkinson's disease, Pick's disease, Dementia with Lewy Bodies, Prion diseases including Creutzfeldt-Jakob disease, progressive supranuclear palsy, multiple system atrophy, corticobasal degeneration, frontotemporal degeneration with Parkinsonism liked to chromosome 17 Huntington's disease, frontotemporal dementia, cerebral amyloid angiopathy, mild cognitive impairment, Down's syndrome, hereditary cerebral haemorrhage with amyloidosis Dutch type and Icelandic type, spinocerebellar ataxia and amyotrohic lateral sclerosis as well as glaucoma, inclusion body myositis, familial amyloid polyneuropathy and amyloidosis comprising fibrillary proteins derived from at least one of the following precursor proteins SAA (Serum-Amyloid-Protein A), AL (k or l-light chains of Immunoglobulins), AH (gl Ig-heavy chains), ATTR (Transthyretin, Serum-Prealbumin), AApo-A-1 (Apolipoprotein A1), AApoA2 (Apolipoprotein A2), AGel (Gelsolin), ACys (Cystatin C), ALys (Lysozyme), AFib (Fibrinogen), Beta-amyloid2M (beta2-microglobulin), APrP (Prion protein), ACal (Procalcitonin), APro (Prolactin), AIns (Insulin), AMed (Lactadherin), Aker (Kerato-epithelin), ALac (Lactoferrin), Abri (AbriPP), ADan (ADanPP), AANP (Atrial natriurectical peptide), Superoxide dismutase-1 (SOD1), Huntington (containing polyglutamine repeat expansion), or Ataxin (containing polyglutamine repeat expansion).
